# US 2023/0142171 A1 · New benzodiazepine derivatives as gaba a gamma1 pam

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0142171 A1
- Document ID: US20230142171A1
- Status: Published application
- Kind: A1
- Application number: 17/938,000
- Filed: 2022-10-04
- Published: 2023-05-11
- Earliest claimed: 2021-10-06
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Bjoern BARTELS; Giuseppe CECERE; Luca GOBBI; Maria-Clemencia HERNANDEZ; Roland HUMM; Andrés Miguel OLIVARES MORALES; Angélique PATINY-ADAM; Valerie RUNTZ-SCHMITT; Christian SCHNIDER
- Web page: https://patentgrep.com/patent/US20230142171A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 243/24: Oxygen atoms
- C07D 243/26: Preparation from compounds already containing the benzodiazepine skeleton
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.

## Claims

### Claim 1

A compound of formula (I) or (II)
or a pharmaceutically acceptable salt thereof, wherein:
is selected from:
X is selected from C—R6 and nitrogen;
W is C or N;
R1 is selected from hydrogen, C1-C6-alkyl, carbamoyl, C1-C6-alkyl-NH—C(O)—, (C1-C6-alkyl)2N—C(O)—, C3-C10-cycloalkyl-NH—C(O)—, and 3-14-membered heterocycloalkyl-C(O)—; wherein said 3-14-membered heterocycloalkyl is optionally substituted by 1 substituent selected from halogen and C1-C6-alkoxy;
R1a is selected from hydrogen and C1-C6-alkyl; or
R1 and R1a, taken together with the carbon atoms to which they are attached, form a C3-C10-cycloalkenyl;
R2 is selected from hydrogen and C1-C6-alkyl;
R3 is selected from chloro and bromo;
R4 is selected from C1-C3-alkyl, halo-C1-C2-alkyl, and halogen;
R5 is selected from hydrogen and halogen; and
R6 is selected from hydrogen and halogen.

### Claim 2 (depends on 1)

The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
is selected from:
R1 is selected from hydrogen, C1-C6-alkyl, and 3-14-membered heterocycloalkyl-C(O)—; wherein said 3-14-membered heterocycloalkyl is substituted by 1 C1-C6-alkoxy substituent; and
R1a is C1-C6-alkyl.

### Claim 3 (depends on 2)

The compound of formula (I) or (II) according to claim 2, or a pharmaceutically acceptable salt thereof, wherein
is selected from:
R1 is selected from hydrogen, methyl, and methoxyazetidine-C(O)—; and
R1a is methyl.

### Claim 4 (depends on 1)

The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from hydrogen and methyl.

### Claim 5 (depends on 1)

The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is chloro.

### Claim 6 (depends on 1)

The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from methyl, CF3, and chloro.

### Claim 7 (depends on 1)

The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R5 is halogen.

### Claim 8 (depends on 7)

The compound of formula (I) or (II) according to claim 7, or a pharmaceutically acceptable salt thereof, wherein R5 is selected from chloro and fluoro.

### Claim 9 (depends on 1)

The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen.

### Claim 10 (depends on 1)

The compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
is selected from:
X is selected from C—R6 and nitrogen;
R1 is selected from hydrogen, C1-C6-alkyl, C1-C6-alkyl-NH—C(O)—, C3-C10-cycloalkyl-NH—C(O)—, and 3-14-membered heterocycloalkyl-C(O)—; wherein said 3-14-membered heterocycloalkyl is optionally substituted by 1 substituent selected from halogen and C1-C6-alkoxy;
R1a is selected from hydrogen and C1-C6-alkyl; or
R1 and R1a, taken together with the carbon atoms to which they are attached, form a C3-C10-cycloalkenyl;
R2 is selected from hydrogen and C1-C6-alkyl;
R3 is chloro;
R4 is selected from C1-C3-alkyl, halo-C1-C2-alkyl, and halogen;
R5 is halogen; and
R6 is selected from hydrogen and halogen.

### Claim 11 (depends on 10)

The compound of formula (I) or (II) according to claim 10, or a pharmaceutically acceptable salt thereof, wherein:
is selected from:
X is selected from C—R6 and nitrogen;
R1 is selected from hydrogen, C1-C6-alkyl, and 3-14-membered heterocycloalkyl-C(O)—;
wherein said 3-14-membered heterocycloalkyl is substituted by 1 C1-C6-alkoxy substituent;
R1a is C1-C6-alkyl;
R2 is selected from hydrogen and C1-C6-alkyl;
R3 is chloro;
R4 is selected from C1-C3-alkyl, halo-C1-C2-alkyl, and halogen;
R5 is halogen; and
R6 is hydrogen.

### Claim 12 (depends on 11)

The compound of formula (I) or (II) according to claim 11, or a pharmaceutically acceptable salt thereof, wherein:
is selected from:
X is selected from C—R and nitrogen;
R1 is selected from hydrogen, methyl, and methoxyazetidine-C(O)—;
R1a is methyl;
R2 is selected from hydrogen and methyl;
R3 is chloro;
R4 is selected from methyl, CF3, and chloro;
R5 is selected from chloro and fluoro; and
R6 is hydrogen.

### Claim 13

A compound of formula (I) or (II), or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) or (II) is selected from:
6,7-dichloro-5-(2-fluoro-5-hydroxyphenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one;
6-chloro-5-(2-fluoro-5-hydroxyphenyl)-1,7-dimethyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one;
3-(7,8-dichloro-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl)-4-fluoro-phenol;
3-[(4S)-7,8-dichloro-1,4-dimethyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl]-4-fluorophenol;
(5S)-8,9-dichloro-7-(2-fluoro-5-hydroxyphenyl)-5-methyl-5H-pyrimido[1,2-a][1,4]benzodiazepin-3-one;
8,9-dichloro-7-(2-fluoro-5-hydroxy-phenyl)-5H-pyrimido[1,2-a][1,4]benzodiazepin-3-one;
[7,8-dichloro-6-(2-fluoro-5-hydroxy-phenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepin-2-yl]-(3-methoxyazetidin-1-yl)methanone;
6-chloro-5-(2-fluoro-5-hydroxy-phenyl)-1-methyl-7-(trifluoromethyl)-3H-1,4-benzodiazepin-2-one;
3-[7-chloro-1-methyl-8-(trifluoromethyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl]-4-fluoro-phenol;
3-[7-chloro-8-(trifluoromethyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl]-4-fluoro-phenol;
3-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl]-4-fluoro-phenol;
8-chloro-7-(2-fluoro-5-hydroxy-phenyl)-9-(trifluoromethyl)-5H-pyrimido[1,2-a][1,4]benzodiazepin-3-one;
6,7-dichloro-5-(2,6-difluoro-3-hydroxy-phenyl)-1-methyl-3H-1,4-benzodiazepin-2-one;
3-(7,8-dichloro-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl)-2,4-difluoro-phenol;
8,9-dichloro-7-(2,6-difluoro-3-hydroxy-phenyl)-5H-pyrimido[1,2-a][1,4]benzodiazepin-3-one;
3-[(4S)-7,8-dichloro-1,4-dimethyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl]-2,4-difluoro-phenol;
[7-chloro-6-(2-fluoro-5-hydroxy-phenyl)-8-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepin-2-yl]-(3-methoxyazetidin-1-yl)methanone;
(5S)-8,9-dichloro-7-(2,6-difluoro-3-hydroxy-phenyl)-5-methyl-5H-pyrimido[1,2-a][1,4]benzodiazepin-3-one;
[7-chloro-6-(2-fluoro-5-hydroxy-phenyl)-8-(trifluoromethyl)-4H-imidazo[1,5-a][1,4]benzodiazepin-3-yl]-(3-methoxyazetidin-1-yl)methanone;
6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl]-5-fluoro-pyridin-2-ol;
[(4S)-7-chloro-6-(3-fluoro-6-hydroxy-2-pyridyl)-4-methyl-8-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepin-2-yl]-(3-fluoroazetidin-1-yl)methanone;
5-chloro-6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-6-yl]pyridin-2-ol;
6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]-5-fluoro-pyridin-2-ol;
6-[(10S)-6-chloro-10-methyl-5-(trifluoromethyl)-1,9,12-triazatetracyclo[9.6.0.02,7.013,17]heptadeca-2,4,6,8,11,13(17)-hexaen-8-yl]-5-fluoro-pyridin-2-ol;
6-[(4S)-7-chloro-2,4-dimethyl-8-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepin-6-yl]-5-fluoropyridin-2-ol;
5-chloro-6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]pyridin-2-ol;
5-chloro-6-[(4S)-7-chloro-2,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]pyridin-2-ol;
6-[(4S)-7-chloro-2,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]-5-fluoro-pyridin-2-ol;
5-chloro-6-[(4S)-7-chloro-2,4-dimethyl-8-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepin-6-yl]pyridin-2-ol;
azetidin-1-yl-[(4S)-7-chloro-6-(3-fluoro-6-hydroxypyridin-2-yl)-4-methyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-2-yl]methanone;
(4S)-7-chloro-N-cyclopropyl-6-(3-fluoro-6-hydroxy-2-pyridyl)-4-methyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-carboxamide;
(4S)-7-chloro-6-(3-fluoro-6-hydroxy-2-pyridyl)-N-isopropyl-4-methyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-carboxamide.

### Claim 14 (depends on 13)

The compound of formula (I) or (II) according to claim 13, or a pharmaceutically acceptable salt thereof, wherein said compound of formula (I) or (II) is selected from:
6,7-dichloro-5-(2-fluoro-5-hydroxyphenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one;
6-chloro-5-(2-fluoro-5-hydroxyphenyl)-1,7-dimethyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one;
6-chloro-5-(2-fluoro-5-hydroxy-phenyl)-1-methyl-7-(trifluoromethyl)-3H-1,4-benzodiazepin-2-one;
[7-chloro-6-(2-fluoro-5-hydroxy-phenyl)-8-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepin-2-yl]-(3-methoxyazetidin-1-yl)methanone;
6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]-5-fluoro-pyridin-2-ol;
5-chloro-6-[(4S)-7-chloro-1,4-dimethyl-8-(trifluoromethyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-6-yl]pyridin-2-ol.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

### Claim 16 (depends on 1)

A method for treating or preventing acute neurological disorders, chronic neurological disorders and/or cognitive disorders in a subject, said method comprising administering an effective amount of a compound of formula (I) or (II) according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said acute neurological disorders, chronic neurological disorders and/or cognitive disorders are selected from autism spectrum disorders (ASD), Angelman syndrome, age-related cognitive decline, Rett syndrome, Prader-Willi syndrome, amyotrophic lateral sclerosis (ALS), fragile-X disorder, negative and/or cognitive symptoms associated with schizophrenia, tardive dyskinesia, anxiety, social anxiety disorder (social phobia), panic disorder, agoraphobia, generalized anxiety disorder, disruptive, impulse-control and conduct disorders, Tourette's syndrome (TS), obsessive-compulsive disorder (OCD), acute stress disorder, post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), sleep disorders, Parkinson's disease (PD), Huntington's chorea, Alzheimer's disease (AD), mild cognitive impairment (MCI), dementia, behavioral and psychological symptoms (BPS) in neurodegenerative conditions, multi-infarct dementia, agitation, psychosis, substance-induced psychotic disorder, aggression, eating disorders, depression, chronic apathy, anhedonia, chronic fatigue, seasonal affective disorder, postpartum depression, drowsiness, sexual dysfunction, bipolar disorders, epilepsy and pain.

### Claim 18 (depends on 16)

The method according to claim 16, wherein said acute neurological disorders, chronic neurological disorders and/or cognitive disorders are selected from autism spectrum disorders, anxiety or an anxiety disorder, obsessive-compulsive disorder, Tourette's syndrome, or attention deficit hyperactivity disorder.

### Claim 19 (depends on 16)

The method according to claim 16, wherein said acute neurological disorders, chronic neurological disorders and/or cognitive disorders are selected from autism spectrum disorders, anxiety or an anxiety disorder.

### Claim 20 (depends on 16)

The method according to claim 16, wherein said acute neurological disorders, chronic neurological disorders and/or cognitive disorders are selected from obsessive-compulsive disorder, Tourette's syndrome, or attention deficit hyperactivity disorder.
